Migraine Headache - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Migraine Headache > What Your Doctor is Reading About Migraine Headache > Clinical Trials

Clinical Trials

1. Traditional acupuncture in migraine: a controlled, randomized study.

Author: Facco E; Liguori A; Petti F; Zanette G; Coluzzi F; De Nardin M; Mattia C;
Institution: University of Padua - Department of Medico-Surgical Specialties - Sect. Dentistry, Padua, Italy.
Journal: Headache. 2008 Mar;48(3):398-407. Epub 2007 Sep 12.
Abstract URL: Click here to view abstract

2. Subcutaneous histamine versus sodium valproate in migraine prophylaxis: a randomized, controlled, double-blind study.

Author: Millan-Guerrero RO; Isais-Millan R; Barreto-Vizcaino S; Rivera-Castano L; Garcia-Solorzano A; Lopez-Blanca C; Membrila-Maldonado M; Munoz-Solis R;
Institution: Department of Neurology, Unidad de Investigacion Medica en Epidemiologia Clinica, Hospital General de Zona UMF No 1 IMSS, Colima, Mexico.
Journal: Eur J Neurol. 2007 Oct;14(10):1079-84.
Abstract URL: Click here to view abstract

3. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.

Author: Ho TW; Mannix LK; Fan X; Assaid C; Furtek C; Jones CJ; Lines CR; Rapoport AM;
Institution: Merck Research Laboratories, UG 4C-18, PO Box 1000, North Wales, PA 19454-1099, USA. tony_ho@merck.com
Journal: Neurology. 2008 Apr 15;70(16):1304-12. Epub 2007 Oct 3.
Abstract URL: Click here to view abstract

4. The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials.

Author: Dahlof C; Loder E; Diamond M; Rupnow M; Papadopoulos G; Mao L;
Institution
Journal: Health Qual Life Outcomes. 2007 Oct 4;5(1):56.
Abstract URL: Click here to view abstract

5. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.

Author: Diener HC; Agosti R; Allais G; Bergmans P; Bussone G; Davies B; Ertas M; Lanteri-Minet M; Reuter U; Del Rio MS; Schoenen J; Schwalen S; van Oene J;
Institution: Department of Neurology, Universitat Duisburg-Essen, Germany. hans.diener@uni-duisburg-essen.de
Journal: Lancet Neurol. 2007 Dec;6(12):1054-62. Epub 2007 Nov 7.
Abstract URL: Click here to view abstract

6. A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine.

Author: Friedman BW; Esses D; Solorzano C; Dua N; Greenwald P; Radulescu R; Chang E; Hochberg M; Campbell C; Aghera A; Valentin T; Paternoster J; Bijur P; Lipton RB; Gallagher EJ;
Institution: Department of Emergency Medicine, Albert Einstein College of Medicine, Bronx, NY 10467, USA. befriedm@montefiore.org
Journal: Ann Emerg Med. 2008 Oct;52(4):399-406. Epub 2007 Nov 19.
Abstract URL: Click here to view abstract

7. Single-dose intravenous tramadol for acute migraine pain in adults: a single-blind, prospective, randomized, placebo-controlled clinical trial.

Author: Alemdar M; Pekdemir M; Selekler HM;
Institution: Department of Neurology, Medical Faculty, Kocaeli University Hospital, Kocaeli, Turkey. drmuratalemdar@yahoo.com
Journal: Clin Ther. 2007 Jul;29(7):1441-7.
Abstract URL: Click here to view abstract

8. Is the Migraid device an asset in the non-pharmacologic treatment of migraine?

Author: Pieterse H; Kuster JA; Van Bortel LM;
Institution: Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium. pieterse@profess.nl
Journal: Acta Neurol Belg. 2007 Jun;107(2):40-6.
Abstract URL: Click here to view abstract

9. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.

Author: Mannix LK; Savani N; Landy S; Valade D; Shackelford S; Ames MH; Jones MW;
Institution: Headache Associates, 7908 Cincinnati-Dayton Road, West Chester, OH 45069, USA.
Journal: Headache. 2007 Jul-Aug;47(7):1037-49.
Abstract URL: Click here to view abstract

10. Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients.

Author: Garcia-Monco JC; Foncea N; Bilbao A; Ruiz de Velasco I; Gomez-Beldarrain M;
Institution: Service of Neurology, Hospital de Galdacano, Vizcaya, Spain. hospit05@sarenet.es
Journal: Cephalalgia. 2007 Aug;27(8):920-8. Epub 2007 Jul 23.
Abstract URL: Click here to view abstract

11. Butterbur root extract and music therapy in the prevention of childhood migraine: an explorative study.

Author: Oelkers-Ax R; Leins A; Parzer P; Hillecke T; Bolay HV; Fischer J; Bender S; Hermanns U; Resch F;
Institution: Department of Child and Adolescent Psychiatry, University of Heidelberg, Blumenstrasse 8, D-69115 Heidelberg, Germany. rieke_oelkers@med.uni-heidelberg.de
Journal: Eur J Pain. 2008 Apr;12(3):301-13. Epub 2007 Jul 30.
Abstract URL: Click here to view abstract

12. Time course of adverse events most commonly associated with topiramate for migraine prevention.

Author: Lainez MJ; Freitag FG; Pfeil J; Ascher S; Olson WH; Schwalen S;
Institution: University Clinic Hospital, University of Valencia, Valencia, Spain. jlaineza@meditex.es
Journal: Eur J Neurol. 2007 Aug;14(8):900-6.
Abstract URL: Click here to view abstract

13. Efficacy of zolmitriptan nasal spray in adolescent migraine.

Author: Lewis DW; Winner P; Hershey AD; Wasiewski WW;
Institution: Division of Pediatric Neurology, Children's Hospital of the King's Daughters, Eastern Virginia Medical School, Norfolk, VA 23510, USA. dlewis@chkd.org
Journal: Pediatrics. 2007 Aug;120(2):390-6.
Abstract URL: Click here to view abstract

14. Greater occipital nerve block using local anaesthetics alone or with triamcinolone for transformed migraine: a randomised comparative study.

Author: Ashkenazi A; Matro R; Shaw JW; Abbas MA; Silberstein SD;
Institution: Department of Neurology, Thomas Jefferson University, 111 South 11th Street, Suite 8130, Philadelphia, PA 19107, USA. avi.ashkenazi@jefferson.edu
Journal: J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):415-7. Epub 2007 Aug 6.
Abstract URL: Click here to view abstract

15. Analysis of pooled data from two pivotal controlled trials on the efficacy of topiramate in the prevention of migraine.

Author: Freitag FG; Forde G; Neto W; Wang DZ; Schmitt J; Wu SC; Hulihan J;
Institution: Diamond Headache Clinic, 467 W Deming Place, Chicago, IL 60614-1881, USA. dhcdoc@aol.com.
Journal: J Am Osteopath Assoc. 2007 Jul;107(7):251-8.
Abstract URL: Click here to view abstract

16. Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headache.

Author: Rowe BH; Colman I; Edmonds ML; Blitz S; Walker A; Wiens S;
Institution: School of Public Health, University of Alberta, Edmonton, Alberta, Canada.
Journal: Headache. 2008 Mar;48(3):333-40. Epub 2007 Nov 28.
Abstract URL: Click here to view abstract

17. Prediction of attack frequency in migraine treatment.

Author: Maas HJ; Snelder N; Danhof M; Della Pasqua O;
Institution: Division of Pharmacology, Leiden/Amsterdam Center for Drug Research, the Netherlands.
Journal: Cephalalgia. 2008 Aug;28(8):847-55. Epub 2008 Jun 6.
Abstract URL: Click here to view abstract

18. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine.

Author: Silberstein SD; Mannix LK; Goldstein J; Couch JR; Byrd SC; Ames MH; McDonald SA; Lener SE; Silberstein SD; Mannix LK; Goldstein J; Couch JR; Byrd SC; Ames MH; McDonald SA; Lener SE;
Institution: Jefferson Headache Center, 111 South 11th Street, Suite 8130, Philadelphia, PA 19107, USA. stephen.silberstein@jefferson.edu
Journal: Neurology. 2008 Jul 8;71(2):114-21.
Abstract URL: Click here to view abstract

19. Aerobic exercise with relaxation: influence on pain and psychological well-being in female migraine patients.

Author: Dittrich SM; Gunther V; Franz G; Burtscher M; Holzner B; Kopp M;
Institution: Center of Psychiatry and Psychotherapy, Department of General and Social Psychiatry, Innsbruck Medical University, Innsbruck, Austria.
Journal: Clin J Sport Med. 2008 Jul;18(4):363-5.
Abstract URL: Click here to view abstract

20. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study.

Author: Silberstein S; Saper J; Berenson F; Somogyi M; McCague K; D'Souza J;
Institution: Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA. Stephen.Silberstein@Jefferson.edu
Journal: Neurology. 2008 Feb 12;70(7):548-55.
Abstract URL: Click here to view abstract

21. Intravenous dexamethasone vs placebo as adjunctive therapy to reduce the recurrence rate of acute migraine headaches: a multicenter, double-blinded, placebo-controlled randomized clinical trial.

Author: Donaldson D; Sundermann R; Jackson R; Bastani A;
Institution: William Beaumont Hospital. ddonaldson87@hotmail.com
Journal: Am J Emerg Med. 2008 Feb;26(2):124-30.
Abstract URL: Click here to view abstract

22. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan.

Author: Goadsby PJ; Zanchin G; Geraud G; de Klippel N; Diaz-Insa S; Gobel H; Cunha L; Ivanoff N; Falques M; Fortea J;
Institution: Headache Group, Institute of Neurology, London, UK. peterg@ion.ucl.ac.uk
Journal: Cephalalgia. 2008 Apr;28(4):383-91. Epub 2008 Feb 20.
Abstract URL: Click here to view abstract

23. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial.

Author: Freitag F; Smith T; Mathew N; Rupnow M; Greenberg S; Mao L; Finlayson G; Wright P; Biondi D;
Institution: Diamond Headache Clinic, LTD., Chicago, IL, USA.
Journal: Headache. 2008 Mar;48(3):341-54.
Abstract URL: Click here to view abstract

24. A double-blind, randomized, placebo-controlled, single-dose study of the cyclooxygenase-2 inhibitor, GW406381, as a treatment for acute migraine.

Author: Wentz AL; Jimenez TB; Dixon RM; Aurora SK; Gold M;
Institution: Migraine Clinical Development, Neurosciences Medicines Development Center, GlaxoSmithKline, NC, USA. alison.l.wentz@gsk.com
Journal: Eur J Neurol. 2008 Apr;15(4):420-7. Epub 2008 Feb 26.
Abstract URL: Click here to view abstract

25. Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache.

Author: Dowson A; Mullen MJ; Peatfield R; Muir K; Khan AA; Wells C; Lipscombe SL; Rees T; De Giovanni JV; Morrison WL; Hildick-Smith D; Elrington G; Hillis WS; Malik IS; Rickards A;
Institution: The King's Headache Service, King's College Hospital, Denmark Hill, London SE5 9RS, UK. dr.dowson@btopenworld.com
Journal: Circulation. 2008 Mar 18;117(11):1397-404. Epub 2008 Mar 3.
Abstract URL: Click here to view abstract

26. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).

Author: Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Institution: Houston Headache Clinic, Houston, TX 77004, USA.
Journal: Headache. 2007 Feb;47(2):189-98.
Abstract URL: Click here to view abstract

27. Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan.

Author: Diez FI; Straube A; Zanchin G;
Institution: Department of Neurology, Hospital General Yague, Avda. Del Cid 96, 09005 Burgos, Spain. iglesias@hgy.es
Journal: J Neurol. 2007 Feb;254(2):242-9. Epub 2007 Mar 2.
Abstract URL: Click here to view abstract

28. Impact of topiramate migraine prophylaxis on workplace productivity: results from two US randomized, double-blind, placebo-controlled, multicenter trials.

Author: Lofland JH; Gagne JJ; Pizzi LT; Rupnow M; Silberstein SD;
Institution: Department of Health Policy (Drs Lofland, Gagne, and Pizzi), Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA. jennifer.lofland@jefferson.edu
Journal: J Occup Environ Med. 2007 Mar;49(3):252-7.
Abstract URL: Click here to view abstract

29. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache.

Author: Limmroth V; Biondi D; Pfeil J; Schwalen S;
Institution: Department of Neurology, Cologne City Hospitals, Cologne, Germany.
Journal: Headache. 2007 Jan;47(1):13-21.
Abstract URL: Click here to view abstract

30. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis.

Author: Magis D; Ambrosini A; Sandor P; Jacquy J; Laloux P; Schoenen J;
Institution: Headache Research Unit, Neurology Department, University of Liege, Liege, Belgium.
Journal: Headache. 2007 Jan;47(1):52-7.
Abstract URL: Click here to view abstract

31. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine.

Author: Hershey AD; Powers SW; Vockell AL; Lecates SL; Ellinor PL; Segers A; Burdine D; Manning P; Kabbouche MA;
Institution: Division of Neurology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.
Journal: Headache. 2007 Jan;47(1):73-80.
Abstract URL: Click here to view abstract

32. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy.

Author: Lainez MJ; Galvan J; Heras J; Vila C;
Institution: Neurology Department, Hospital Clinic Universitari, University of Valencia, Valencia, Spain. jlaineza@meditex.es
Journal: Eur J Neurol. 2007 Mar;14(3):269-75.
Abstract URL: Click here to view abstract

33. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

Author: Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
Institution: Jefferson Headache Center, Philadelphia, PA 19107, USA.
Journal: Headache. 2007 Feb;47(2):170-80.
Abstract URL: Click here to view abstract

34. Almotriptan and zolmitriptan in the acute treatment of migraine.

Author: Goadsby PJ; Massiou H; Pascual J; Diener HC; Dahlof CG; Mateos V; Dowson AJ; Raets I; Cunha L; Farkkila M; Manzoni GC;
Institution: Headache Group, Institute of Neurology, Queen Square, London, UK. peterg@ion.ucl.ac.uk
Journal: Acta Neurol Scand. 2007 Jan;115(1):34-40.
Abstract URL: Click here to view abstract

35. Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray for treatment of migraine in real-life practice: results of a postmarketing surveillance study.

Author: Diener HC; Evers S;
Institution: Department of Neurology, University of Duisburg-Essen, Essen, Germany. hans.diener@uni-duisburg-essen.de
Journal: Clin Drug Investig. 2007;27(1):59-66.
Abstract URL: Click here to view abstract

36. Testing the combination beta-blocker plus topiramate in refractory migraine.

Author: Pascual J; Rivas MT; Leira R;
Institution: Service of Neurology, University Hospital, Salamanca, Spain. juliopascual@telefonica.net
Journal: Acta Neurol Scand. 2007 Feb;115(2):81-3.
Abstract URL: Click here to view abstract

37. Diclofenac epolamine is effective in the treatment of acute migraine attacks. A randomized, crossover, double blind, placebo-controlled, clinical study.

Author: Vecsei L; Gallacchi G; Sagi I; Semjen J; Tajti J; Szok D; Muller M; Vadass P; Kerekgyarto M;
Institution: Department of Neurology, Albert Szent-Gyorgyi Medical and Pharmaceutical Centre, University of Szeged and Neurology Research Group of the Hungarian Academy of Sciences and University of Szeged, Szeged, Hungary. giuseppe.mautone@ibsa.ch
Journal: Cephalalgia. 2007 Jan;27(1):29-34.
Abstract URL: Click here to view abstract

38. Sumatriptan 6 mg subcutaneous as an effective migraine treatment in patients with cutaneous allodynia who historically fail to respond to oral triptans.

Author: Diamond S; Freitag FG; Feoktistov A; Nissan G;
Institution: Diamond Headache Clinic, 467 West Deming Place, Suite 500, Chicago, IL 60614, USA. MACF48@aol.com
Journal: J Headache Pain. 2007 Feb;8(1):13-8. Epub 2007 Jan 15.
Abstract URL: Click here to view abstract

39. How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate.

Author: Pascual J; El Berdei Y; Gomez-Sanchez JC;
Institution: Service of Neurology, University Hospital, Paseo de San Vicente 58-132, 37007, Salamanca, Spain. juliopascual@telefonica.net
Journal: J Headache Pain. 2007 Apr;8(2):90-3. Epub 2007 Jan 15.
Abstract URL: Click here to view abstract

40. Effectiveness of ropivacaine trigger points inactivation in the prophylactic management of patients with severe migraine.

Author: Garcia-Leiva JM; Hidalgo J; Rico-Villademoros F; Moreno V; Calandre EP;
Institution: Instituto de Neurociencias, Universidad de Granada, Granada, Spain.
Journal: Pain Med. 2007 Jan-Feb;8(1):65-70.
Abstract URL: Click here to view abstract

41. Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine.

Author: Winner P; Cady RK; Ruoff GE; Frishberg BM; Alexander WJ; Zhang Y; Kori SH; Lener SE;
Institution: Palm Beach Headache Center, 4631 N Congress Ave, Suite 200, West Palm Beach, FL 33407, USA. eneuro@aol.com
Journal: Mayo Clin Proc. 2007 Jan;82(1):61-8.
Abstract URL: Click here to view abstract

42. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study).

Author: Gupta P; Singh S; Goyal V; Shukla G; Behari M;
Institution: Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
Journal: Headache. 2007 Mar;47(3):402-12.
Abstract URL: Click here to view abstract

43. Effectiveness of yoga therapy in the treatment of migraine without aura: a randomized controlled trial.

Author: John PJ; Sharma N; Sharma CM; Kankane A;
Institution: Department of Zoology, University of Rajasthan, Jaipur, Rajasthan, India.
Journal: Headache. 2007 May;47(5):654-61.
Abstract URL: Click here to view abstract

44. Efficacy of eletriptan in migraine-related functional impairment: functional and work productivity outcomes.

Author: Silberstein SD; Cady RK; Sheftell FD; Almas M; Parsons B; Albert KS;
Institution: Jefferson Headache Center, Philadelphia, PA 19107, USA.
Journal: Headache. 2007 May;47(5):673-82.
Abstract URL: Click here to view abstract

45. Sumatriptan/Naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomes.

Author: Smith T; Blumenthal H; Diamond M; Mauskop A; Ames M; McDonald S; Lener S; Burch S;
Institution: Mercy Health Research and Ryan Headache Center, St. Louis, MO 63141, USA.
Journal: Headache. 2007 May;47(5):683-92.
Abstract URL: Click here to view abstract

46. Efficacy of lisinopril in migraine prophylaxis--an open label study.

Author: Schuh-Hofer S; Flach U; Meisel A; Israel H; Reuter U; Arnold G;
Institution: Department of Neurology, Universitatsklinikum Tuebingen, Tuebingen, Germany.sigrid.schuh-hofer@gmx.net
Journal: Eur J Neurol. 2007 Jun;14(6):701-3.
Abstract URL: Click here to view abstract

47. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial.

Author: Silberstein SD; Young WB; Hopkins MM; Gebeline-Myers C; Bradley KC;
Institution: Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Journal: Headache. 2007 Jun;47(6):878-85.
Abstract URL: Click here to view abstract

48. Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine.

Author: Brandes JL; Smith T; Diamond M; Ames MH;
Institution: Department of Neurology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Journal: Headache. 2007 Jun;47(6):886-94.
Abstract URL: Click here to view abstract

49. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.

Author: Brandes JL; Kudrow D; Stark SR; O'Carroll CP; Adelman JU; O'Donnell FJ; Alexander WJ; Spruill SE; Barrett PS; Lener SE;
Institution: Nashville Neuroscience Group, Nashville, Tenn 37203, USA. jbrandes@nashvilleneuroscience.com
Journal: JAMA. 2007 Apr 4;297(13):1443-54.
Abstract URL: Click here to view abstract

50. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.

Author: Relja M; Poole AC; Schoenen J; Pascual J; Lei X; Thompson C;
Institution: Department of Neurology, Medical School University of Zagreb, Zagreb, Croatia. mrelja@mef.hr
Journal: Cephalalgia. 2007 Jun;27(6):492-503. Epub 2007 Apr 11.
Abstract URL: Click here to view abstract

51. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Author: Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
Institution: Department of Neurology, University of Duisburg-Essen, Germany.
Journal: Cephalalgia. 2007 Jul;27(7):814-23. Epub 2007 Apr 18.
Abstract URL: Click here to view abstract

52. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden.

Author: Bigal M; Rapoport A; Aurora S; Sheftell F; Tepper S; Dahlof C;
Institution: Albert Einstein College of Medicine--Neurology, Bronx, NY 10461, USA.
Journal: Headache. 2007 Apr;47(4):475-9.
Abstract URL: Click here to view abstract

53. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.

Author: Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Institution: Swedish Pain Center, Seattle, WA 98104, USA.
Journal: Headache. 2007 Apr;47(4):486-99.
Abstract URL: Click here to view abstract

54. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.

Author: Winner P; Linder SL; Lipton RB; Almas M; Parsons B; Pitman V;
Institution: Nova Southeastern University, Fort Lauderdale, FL 33407, USA.
Journal: Headache. 2007 Apr;47(4):511-8.
Abstract URL: Click here to view abstract

55. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).

Author: Freitag FG; Finlayson G; Rapoport AM; Elkind AH; Diamond ML; Unger JR; Fisher AC; Armstrong RB; Hulihan JF; Greenberg SJ;
Institution: Diamond Headache Clinic, Ltd, Chicago, IL 60614, USA.
Journal: Headache. 2007 Apr;47(4):519-30.
Abstract URL: Click here to view abstract

56. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies.

Author: Mannix LK; Loder E; Nett R; Mueller L; Rodgers A; Hustad CM; Ramsey KE; Skobieranda F;
Institution: Headache Associates and ClinExcel Research, West Chester, OH 45069, USA. lkmannixmd@aol.com
Journal: Cephalalgia. 2007 May;27(5):414-21.
Abstract URL: Click here to view abstract